News - olaparib

Filter

Current filters:

olaparib

Popular Filters

ASCO 2014 kicks off with news on lenvatinib, Cyramza, olaparib and Recentin

ASCO 2014 kicks off with news on lenvatinib, Cyramza, olaparib and Recentin

01-06-2014

The 2014 Annual Meeting of the American Society of Clinical Oncology (ASCO) began on Friday in Chicago,…

AstraZenecaBiotechnologyCyramzaEisaiEli LillylenvatinibolaparibOncologyRecentinResearch

US FDA grants priority review for AstraZeneca’s olaparib

US FDA grants priority review for AstraZeneca’s olaparib

30-04-2014

The US Food and Drug Administration has granted Priority Review for Anglo-Swedish drug major AstraZeneca’s…

AstraZenecaolaparibOncologyPharmaceuticalRegulationUK

Olaparib-resistant ovarian cancer patients live longer also treated with chemotherapy

Olaparib-resistant ovarian cancer patients live longer also treated with chemotherapy

11-10-2013

Conventional chemotherapy could further extend life in some women with ovarian cancer when used in tandem…

AstraZenecaEuropeolaparibOncologyPharmaceuticalResearch

AstraZeneca's starts olaparib in Ph III for ovarian cancer

04-09-2013

Anglo-Swedish drug major AstraZeneca (LSE: AZN) says it has enrolled the first patient in the Phase III…

AstraZenecaMarkets & MarketingMyriad GeneticsolaparibOncologyPharmaceuticalResearch

AstraZeneca plans to move three cancer drug candidates into Ph III

16-05-2013

Anglo-Swedish drug major AstraZeneca (LSE: AZN) this morning (May 16) announced that it will be moving…

AstraZenecaBiotechnologyMedImmunemoxetumomab pasudotoxolaparibOncologyPharmaceuticalResearchselumetinib

Double R&D setback for AstraZeneca; new deal for cancer candidate

21-12-2011

Anglo-Swedish drug major AstraZeneca (LSE: AZ) had a double dose of bad news, when the company said that…

Hutchison MediPharmaLicensingNeurologicalolaparibOncologyPharmaceuticalResearchTargaceptvolitinib

Company Spotlight

Eleven Biotherapeutics

Eleven Biotherapeutics

Back to top